----

*Exhibit 99.1*
|  |  Progenics Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, New York 10591Fax: (914) 789-2817(914) 789-2800www.progenics.com  |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·       |  | In April, Progenics and Valeant announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR® Subcutaneous Injection for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Additionally, the Committee recommended a one-year extension of data protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies.  |
|--------------|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ·       |  | Also in April, Progenics reported that its Japanese partner, FUJIFILM RI Pharma Co. Ltd. had dosed the first patient in its early Phase 2 trial of 1404 in Japan.  The trial will evaluate 1404 in newly-diagnosed prostate cancer patients with lymph node and/or bone metastases or at high risk for metastatic disease.                                                                                                                                                                                                                                                                                                            |
|         |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ·       |  | In March, Dr. Shankar Vallabhajosula, Ph.D. and Dr. Scott T. Tagawa, M.D., both of Weill Cornell Medical College, initiated an investigator-sponsored Phase 2 study designed to evaluate 1404 in approximately 12 men with metastatic castration-resistant prostate cancer who plan to initiate androgen resistant-pathway targeted therapy.                                                                                                                                                                                                                                                                                               |
|         |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ·       |  | In February, the Company presented positive Phase 2 data for PSMA ADC in patients with metastatic castration-resistant prostate cancer at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including new data from the recently completed chemo-naïve cohort. Treatment with PSMA ADC reduced tumor size and levels of PSA and CTCs (circulating tumor cells), evidencing strong anti-tumor activity and a generally well tolerated safety profile with neutropenia the most common treatment related adverse event.                                                                                        |
|         |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ·  |  | In January, Progenics announced that the first patient had been dosed in the resumed pivotal Phase 2 study of AzedraTM in patients with malignant pheochromocytoma and paraganglioma, an ultra-orphan indication.                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

| PROGENICS PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except net loss per share) |   |
|--------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                     |   | For the Three Months EndedMarch 31, |   |
|                                                                                                                     |   | 2015 |   |   | 2014 |   |
| Revenues:                                                                                                                |   |  |   |   |  |   |
|   Royalty income                                                                                               |   | $ | 174 |   |   | $ | 735 |   |
|   Collaboration revenue                                                                                        |   |   | 65 |   |   |   | 1,049 |   |
|   Other revenues                                                                                               |   |   | 9 |   |   |   | 31 |   |
|      Total revenues                                                                             |   |   | 248 |   |   |   | 1,815 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |
| Expenses:                                                                                                                |   |   |   |   |   |   |   |   |
|    Research and development                                                                               |   |   | 6,463 |   |   |   | 6,919 |   |
|    License fees – research and development                                                          |   |   | (16 | ) |   |   | 90 |   |
|    Royalty expense                                                                                        |   |   | 42 |   |   |   | 82 |   |
|    General and administrative                                                                             |   |   | 3,593 |   |   |   | 3,405 |   |
|    Depreciation and amortization                                                                          |   |   | 132 |   |   |   | 144 |   |
|    Change in contingent consideration liability                                                           |   |   | 300 |   |   |   | 500 |   |
|       Total expenses                                                                       |   |   | 10,514 |   |   |   | 11,140 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |
| Operating loss                                                                                                           |   |   | (10,266 | ) |   |   | (9,325 | ) |
|                                                                                                                     |   |   |   |   |   |   |   |   |
| Other income:                                                                                                            |   |   |   |   |   |   |   |   |
|    Interest income                                                                                        |   |   | 12 |   |   |   | 12 |   |
|       Total other income                                                                   |   |   | 12 |   |   |   | 12 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                 |   | $ | (10,254 | ) |   | $ | (9,313 | ) |
|                                                                                                                     |   |   |   |   |   |   |   |   |
| Net loss per share; basic and diluted                                                                                    |   | $ | (0.15 | ) |   | $ | (0.15 | ) |
| Weighted average shares outstanding; basic and diluted                                                                   |   |   | 69,637 |   |   |   | 63,958 |   |

| CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands) |   |
|-----------------------------------------------------|--------|
|                                                |   | March 31,2015 |   |   | December 31,2014 |   |
|                                                |   | (unaudited) |   |   |  |   |
|                                                |   |  |   |   |  |   |
| Cash and cash equivalents                           |   | $ | 108,430 |   |   | $ | 119,302 |   |
| Accounts receivable, net                            |   |   | 152 |   |   |   | 109 |   |
| Fixed assets, net                                   |   |   | 2,473 |   |   |   | 2,552 |   |
| Intangible assets, net and goodwill                 |   |   | 36,402 |   |   |   | 36,402 |   |
| Other assets                                        |   |   | 3,163 |   |   |   | 2,672 |   |
|    Total assets                      |   | $ | 150,620 |   |   | $ | 161,037 |   |
|                                                |   |   |   |   |   |   |   |   |
| Current liabilities                                 |   | $ | 5,416 |   |   | $ | 6,685 |   |
| Contingent consideration liability                  |   |   | 17,500 |   |   |   | 17,200 |   |
| Deferred tax and other liabilities                  |   |   | 12,231 |   |   |   | 12,243 |   |
|     Total liabilities           |   |   | 35,147 |   |   |   | 36,128 |   |
|     Stockholders' equity        |   |   | 115,473 |   |   |   | 124,909 |   |
| Total liabilities and stockholders' equity          |   | $ | 150,620 |   |   | $ | 161,037 |   |

----

----

----

| Contact:  | Melissa DownsInvestor Relations(914) 789-2801mdowns@progenics.com |
|----------------|-------------------------------------------------------------------|